Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2008

01-02-2008 | Article

Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis

Authors: M. Fleischhacker, C. Radecke, B. Schulz, M. Ruhnke

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2008

Login to get access

Abstract

Objectives To analyze the effects of a high concentration of three antifungal substances, the echinocandins anidulafungin, caspofungin, and micafungin, on the growth of Candida spp. Methods The growth of 127 C. dubliniensis isolates and 103 C. albicans isolates cultured in medium containing anidulafungin, caspofungin, or micafungin was analyzed using a broth microdilution test according to the guidelines of the CLSI M27-A2 [NCCLS (1997), Wayne, PA]. The final concentrations of all three echinocandins ranged from 0.125 to 64 μg/L. Results The different effects of these three antifungal substances on C. albicans cells in comparison to C. dubliniensis cells were quite distinct. When both Candida species were grown in the presence of anidulafungin only a trailing effect was observed. Micafungin induced an Eagle effect in C. dubliniensis only (63%), while caspofungin induced this effect in the majority of C. dubliniensis isolates (90%) and in only a few C. albicans isolates (14%). Conclusions Based on our observations, anidulafungin has effects that are different from the ones produced by micafungin and caspofungin. Whether this different response to high concentrations of echinocandins is based on genetic or phenotypic differences between C. albicans and C. dubliniensis has to be determined in future experiments.
Literature
1.
2.
go back to reference Morris MI, Villmann M (2006) Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 63:1693–1703PubMedCrossRef Morris MI, Villmann M (2006) Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 63:1693–1703PubMedCrossRef
3.
go back to reference Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–3411PubMedCrossRef Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–3411PubMedCrossRef
4.
go back to reference Stevens DA, White TC, Perlin DS, Selitrennikoff CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51:173–178PubMedCrossRef Stevens DA, White TC, Perlin DS, Selitrennikoff CP (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51:173–178PubMedCrossRef
5.
go back to reference St-Germain G (1990) Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother 34:2304–2306PubMed St-Germain G (1990) Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother 34:2304–2306PubMed
6.
go back to reference Arai R, Sugita T, Nishikawa A (2005) Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses 48:38–41PubMedCrossRef Arai R, Sugita T, Nishikawa A (2005) Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses 48:38–41PubMedCrossRef
7.
go back to reference Arikan S, Sancak B, Hascelik G (2005) In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole againstCandida strains isolated in a Turkish University Hospital. Med Mycol 43:171–178PubMedCrossRef Arikan S, Sancak B, Hascelik G (2005) In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole againstCandida strains isolated in a Turkish University Hospital. Med Mycol 43:171–178PubMedCrossRef
8.
go back to reference Torres-Rodriguez JM, Carrillo-Munoz A, Gallach-Bau C, Madrenys N (1989) Susceptibility of Candida species to cilofungin (LY-121019). Mycoses 32:316–318PubMedCrossRef Torres-Rodriguez JM, Carrillo-Munoz A, Gallach-Bau C, Madrenys N (1989) Susceptibility of Candida species to cilofungin (LY-121019). Mycoses 32:316–318PubMedCrossRef
9.
go back to reference Marr KA, Rustad TR, Rex JH, White TC (1999) The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 43:1383–1386PubMed Marr KA, Rustad TR, Rex JH, White TC (1999) The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 43:1383–1386PubMed
10.
go back to reference Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44:2373–2381PubMedCrossRef Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44:2373–2381PubMedCrossRef
11.
go back to reference Jacobsen MD, Whyte JA, Odds FC (2007)Candida albicans andCandida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 51:1882–1884PubMedCrossRef Jacobsen MD, Whyte JA, Odds FC (2007)Candida albicans andCandida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 51:1882–1884PubMedCrossRef
12.
go back to reference Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154PubMedCrossRef Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154PubMedCrossRef
13.
go back to reference Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN (2003) In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 47:1068–1071PubMedCrossRef Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN (2003) In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 47:1068–1071PubMedCrossRef
14.
go back to reference Espinel-Ingroff A (2003) In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20:121–136PubMed Espinel-Ingroff A (2003) In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20:121–136PubMed
15.
go back to reference Ruhnke M, Schmidt-Westhausen A, Engelmann E, Trautmann M (1996) Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol 34:3208–3211PubMed Ruhnke M, Schmidt-Westhausen A, Engelmann E, Trautmann M (1996) Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol 34:3208–3211PubMed
16.
go back to reference National Committee for Clinical Laboratory Standards (NCCLS) (1997) Reference method for broth dilution antigungal susceptibility testing of yeasts: approved standard, 2nd edn. NCCLS Document M27-A. NCCLS, Wayne, PA National Committee for Clinical Laboratory Standards (NCCLS) (1997) Reference method for broth dilution antigungal susceptibility testing of yeasts: approved standard, 2nd edn. NCCLS Document M27-A. NCCLS, Wayne, PA
17.
go back to reference Hall GS, Myles C, Pratt KJ, Washington JA (1988) Cilofungin (LY121019), an antifungal agent with specific activity againstCandida albicans and Candida tropicalis. Antimicrob Agents Chemother 32:1331–1335PubMed Hall GS, Myles C, Pratt KJ, Washington JA (1988) Cilofungin (LY121019), an antifungal agent with specific activity againstCandida albicans and Candida tropicalis. Antimicrob Agents Chemother 32:1331–1335PubMed
18.
go back to reference Iwata K, Yamamoto Y, Yamaguchi H, Hiratani T (1982) In vitro studies of aculeacin A, a new antifungal antibiotic. J Antibiot (Tokyo) 35:203–209 Iwata K, Yamamoto Y, Yamaguchi H, Hiratani T (1982) In vitro studies of aculeacin A, a new antifungal antibiotic. J Antibiot (Tokyo) 35:203–209
19.
go back to reference Pfaller MA, Wey S, Gerarden T, Houston A, Wenzel RP (1989) Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. Diagn Microbiol Infect Dis 12:1–4PubMedCrossRef Pfaller MA, Wey S, Gerarden T, Houston A, Wenzel RP (1989) Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. Diagn Microbiol Infect Dis 12:1–4PubMedCrossRef
20.
go back to reference Chamilos G, Lewis RE, Albert N, Kontoyiannis DP (2007) Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51:2257–2259PubMedCrossRef Chamilos G, Lewis RE, Albert N, Kontoyiannis DP (2007) Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51:2257–2259PubMedCrossRef
21.
go back to reference Uzun O, Arikan S, Kocagoz S, Sancak B, Unal S (2000) Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 38:101–107PubMedCrossRef Uzun O, Arikan S, Kocagoz S, Sancak B, Unal S (2000) Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 38:101–107PubMedCrossRef
22.
go back to reference Clemons KV, Espiritu M, Parmar R, Stevens DA (2006) Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50:1293–1297PubMedCrossRef Clemons KV, Espiritu M, Parmar R, Stevens DA (2006) Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50:1293–1297PubMedCrossRef
23.
go back to reference Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A (2007) Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51:968–974PubMedCrossRef Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A (2007) Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51:968–974PubMedCrossRef
24.
go back to reference Sutton DA (2002) Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis 15:575–582PubMed Sutton DA (2002) Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis 15:575–582PubMed
25.
go back to reference Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE (2005) International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43:3884–3889PubMedCrossRef Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE (2005) International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43:3884–3889PubMedCrossRef
26.
go back to reference Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G (2006) Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 19:130–139PubMed Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G (2006) Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 19:130–139PubMed
27.
go back to reference Yamaguchi H, Hiratani T, Iwata K, Yamamoto Y (1982) Studies on the mechanism of antifungal action of aculeacin A. J Antibiot (Tokyo) 35:210–219 Yamaguchi H, Hiratani T, Iwata K, Yamamoto Y (1982) Studies on the mechanism of antifungal action of aculeacin A. J Antibiot (Tokyo) 35:210–219
28.
go back to reference Ellepola AN, Hurst SF, Elie CM, Morrison CJ (2003) Rapid and unequivocal differentiation of Candida dubliniensis from other Candida species using species-specific DNA probes: comparison with phenotypic identification methods. Oral Microbiol Immunol 18:379–388PubMedCrossRef Ellepola AN, Hurst SF, Elie CM, Morrison CJ (2003) Rapid and unequivocal differentiation of Candida dubliniensis from other Candida species using species-specific DNA probes: comparison with phenotypic identification methods. Oral Microbiol Immunol 18:379–388PubMedCrossRef
29.
go back to reference Neppelenbroek KH, Campanha NH, Spolidorio DM, Spolidorio LC, Seo RS, Pavarina AC (2006) Molecular fingerprinting methods for the discrimination between C. albicans and C. dubliniensis. Oral Dis 12:242–253 Neppelenbroek KH, Campanha NH, Spolidorio DM, Spolidorio LC, Seo RS, Pavarina AC (2006) Molecular fingerprinting methods for the discrimination between C. albicans and C. dubliniensis. Oral Dis 12:242–253
30.
go back to reference Stevens DA, McCullough MJ, Clemons KV, Martinez MC (2006a) Candida dubliniensis (Cd), a species with an extremely high frequency of paradoxical effect (PE) with caspofungin (CAS). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco Sept 27–30, M-363 Stevens DA, McCullough MJ, Clemons KV, Martinez MC (2006a) Candida dubliniensis (Cd), a species with an extremely high frequency of paradoxical effect (PE) with caspofungin (CAS). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco Sept 27–30, M-363
31.
go back to reference Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H (2006b) Escape of Candida from caspofungin inhibition at supra-MIC concentrations (“Paradoxical effect”) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco Sept 27–30, M-1756 Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H (2006b) Escape of Candida from caspofungin inhibition at supra-MIC concentrations (“Paradoxical effect”) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Francisco Sept 27–30, M-1756
Metadata
Title
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis
Authors
M. Fleischhacker
C. Radecke
B. Schulz
M. Ruhnke
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0411-4

Other articles of this Issue 2/2008

European Journal of Clinical Microbiology & Infectious Diseases 2/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.